Evidence map›Paper›PMID 39408678›Full record

ArticleInternational journal of molecular sciences2024

Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.

Yujiro Nagata, Akinori Minato, Hisami Aono, Rieko Kimuro, Katsuyoshi Higashijima, Ikko Tomisaki, Kenichi Harada, Hiroshi Miyamoto, Naohiro Fujimoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Bladder cancer biomarkers.Exploration of targeted anti-tumor therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yujiro NagataDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Akinori MinatoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Hisami AonoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Rieko KimuroDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Katsuyoshi HigashijimaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Ikko TomisakiDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Kenichi HaradaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Hiroshi MiyamotoDepartments of Pathology & Laboratory Medicine and Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0000-0001-7610-7769
Naohiro FujimotoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.

Funding

Japan Society for the Promotion of Science JP23K15773
6 · The paper itself

Abstract

Locally advanced or metastatic urothelial carcinoma is a genomically and molecularly heterogeneous disease associated with various clinical outcomes. We aimed to evaluate the association between the status of p53/FGFR3 expression and the efficacy of enfortumab vedotin (EV) in metastatic urothelial carcinoma. We evaluated the association between p53 (abnormal vs. wild-type) or FGFR3 (high vs. low) expression determined by immunohistochemistry and response to EV in 28 patients with metastatic urothelial carcinoma. Overall, 60.7% showed abnormal p53, and 17.9% had high FGFR3 expression. The rates of objective response to EV were statistically higher in patients with abnormal p53 than in those with wild-type p53 (

Indexed as

Antibodies, MonoclonalImmunohistochemistryReceptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Protein p53AgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisTreatment OutcomeUrinary Bladder NeoplasmsAntibodies, MonoclonalBiomarkers, Tumorenfortumab vedotinFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3TP53 protein, humanTumor Suppressor Protein p53bladder cancerenfortumab vedotinFGFR3p53upper urinary tract cancerurothelial carcinoma

Identifiers

PMID39408678
PMCPMC11477066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.